Search Within

Jyoti Patel

Formats
  1. Journal Article (6)
  2. Meeting Abstract (1)
Groups
  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (5)
  3. Thoracic Oncology (4)
  4. Nursing (3)
  5. Adult Leukemia (2)
  6. Biostatistics Service (2)

More Groups

People
  1. Lee Krug (4)
  2. Mark Kris (4)
  3. Vincent Miller (4)
  4. Barbara Pizzo (3)
  5. Christopher Azzoli (3)
  6. Jorge Gomez (3)

More People

Years
  1. 2010 (2)
  2. 2006 (1)
  3. 2005 (1)
  4. 2004 (1)
  5. 2003 (2)
Publications
  1. Cancer (2)
  2. Blood (1)
  3. Cancer Cell (1)
  4. EJC Supplements (1)
  5. Journal of Clinical Oncology (1)
  6. Seminars in Oncology (1)
Publishers
  1. Wiley Blackwell (2)
  2. American Society of Clinical Oncology (1)
  3. American Society of Hematology (1)
  4. Cell Press (1)
  5. Elsevier Inc. (1)
  6. Pergamon-Elsevier Science Ltd (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate
    Journal Article

    Ward, P. S.; Patel, J.; Wise, D. R.; Abdel-Wahab, O.; Bennett, B. D.; Coller, H. A.; Cross, J. R.; Fantin, V. R.; Hedvat, C. V.; Perl, A. E.; more...
    Cancer Cell (2010)

    Fulltext@MSK | Save
  • Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
    Journal Article

    Koppikar, P.; Abdel-Wahab, O.; Hedvat, C.; Marubayashi, S.; Patel, J.; Goel, A.; Kucine, N.; Gardner, J. R.; Combs, A. P.; Vaddi, K.; more...
    Blood (2010)

    Fulltext@MSK | Save
  • Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma
    Journal Article

    Johnson, F. M.; Krug, L. M.; Tran, H. T.; Shoaf, S.; Prieto, V. G.; Tamboli, P.; Peeples, B.; Patel, J.; Glisson, B. S.
    Cancer (2006)

    Fulltext@MSK | Save
  • Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
    Journal Article

    Krug, L. M.; Miller, V. A.; Patel, J.; Crapanzano, J.; Azzoli, C. G.; Gomez, J.; Kris, M. G.; Heelan, R. T.; Pizzo, B.; Tyson, L.; more...
    Cancer (2005)

    Fulltext@MSK | Save
  • Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Journal Article

    Miller, V. A.; Kris, M. G.; Shah, N.; Patel, J.; Azzoli, C.; Gomez, J.; Krug, L. M.; Pao, W.; Rizvi, N.; Pizzo, B.; more...
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • The epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib (TarcevaTM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: Interim results of a phase II trial
    Meeting Abstract

    Patel, J.; Miller, V.; Kris, M.; Shah, N.; Tyson, L.; Pizzo, B.; Zakowski, M.; Cespon, M.; Heelan, R.; Johnson, D.
    EJC Supplements (2003)

    Fulltext@MSK | Save
  • Targeting lethal minimal residual disease in small cell lung cancer
    Journal Article

    Patel, J.; Krug, L. M.; Azzoli, C. G.; Gomez, J.; Kris, M. G.; Miller, V. A.
    Seminars in Oncology (2003)

    Fulltext@MSK | Save